🚨 Recommended article 🚨 Swarnali Goswami of the Journal of Medical Economics Early Career Panel has selected "𝐕𝐚𝐥𝐮𝐞 𝐨𝐟 𝐧𝐞𝐱𝐭 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐬𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 (𝐍𝐆𝐒) 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐢𝐧 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐜𝐚𝐧𝐜𝐞𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬" as her recommended read, to find out why, see her post below. Big thanks to the authors for publishing their work in JME. Jesse Ortendahl, Gebra Cuyun Carter, Snehal Thakkar, Katalin Bognar, David Hall, Yara Abdou #healtheconomics #oncology #pharmacoeconomics #cancer #medicaleconomics #HEOR
If you're involved in precision medicine or oncology, I'd like to recommend this article published in the Journal of Medical Economics, which provides crucial insights into the cost-effectiveness and clinical benefits of next-generation genomic testing, particularly the OncoExTra test. 🔑 Key Takeaways: Targeted Therapy Eligibility: Using the OncoExTra test identified 82%–92% of patients with advanced cancers (NSCLC, breast, prostate, colorectal) as eligible for targeted therapies or clinical trials. Cost-Effectiveness: Compared to no testing, OncoExTra added $4,915 per patient. However, compared to single-gene testing, it reduced costs by $9,966 per patient while increasing the use of targeted therapies by 20%. Impact on Health Plans: In a health plan with 1 million members, using OncoExTra in just 5% of eligible patients reduced overall costs, particularly in NSCLC. 💡 This research shows that next-generation sequencing tests like OncoExTra has the potential in terms of improving patient outcomes and lowering healthcare costs compared to single-gene testing. More research is needed to develop stronger testing recommendations and development of coverage policies for the same. Click the link to access the full article 👉https://bit.ly/3YO5LpA #Oncology #GenomicTesting #TargetedTherapy #CancerCare #HealthEconomics #PrecisionMedicine
HEOR Manager
4moThanks Mike for highlighting my post. Congratulations and thank you to all the authors for throwing light for such an important issue